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Drug release from thin films encapsulated by a
temperature-responsive hydrogel
Oliver Werzer, a Stephan Tumphart,b Roman Keimel,a Paul Christianb and
Anna Maria Coclite *b
Control over drug delivery may be interestingly achieved by using temperature responsive encapsulants,
which change their thickness and mesh size with temperature. The prototype N-isopropylacrylamide
hydrogel cross-linked with di(ethylene glycol) divinyl ether p(NIPAAm-co-DEGDVE) swells at low
temperature and collapses above the lower critical solution temperature (LCST), B29 1C in a buﬀer.
It might be expected that drug release from such encapsulation is always favored below the LCST, due
to the larger free volume present in the swollen polymer film. Recent results show contradicting
behavior where some cases behave as expected and others release much less when the polymer layer is
swollen. In this study, layers of the drugs phenytoin, clotrimazole and indomethacin were drop cast on
glass and p(NIPAAM-co-DEGDVE) layers were then synthesized directly on top of these drug layers via
initiated chemical vapor deposition (iCVD), a solvent-free and gentle polymerization technique.
Dissolution experiments were then performed, in which the drug release through the hindrance of the
hydrogel was measured at diﬀerent pH values. The results show that not only the swelling but also the
permeate (drug in this case)–polymer interaction plays an important role in the release.
Introduction
For treatment of a medical condition, diﬀerent drug adminis-
tration routes (e.g., by injection, inhalation, transdermal patches or
by classic oral administration) are available in modern medicine.
Choosing the appropriate administration route will strongly influ-
ence how easily a drug reaches the intended target site, aﬀecting
drug dosage and dosage regimen in turn. It can thus be highly
desirable to control the release behavior of the drug delivery
platform, allowing for example for sustained medication or for
targeted, site-specific drug liberation. The application of a smart
polymer coating is one possible way to obtain control over the
release behavior. In such systems, the polymeric coating can
serve multiple purposes at once. For instance, stabilization of the
solid state of a drug may be achieved by polymeric encapsula-
tion, which limits the environmental exposure.1 At the same
time, these coatings can be beneficial for several therapies as
they enable controlled drug release and minimize severe side
eﬀects due to burst release.2
Stimuli-responsive polymers are currently receiving a lot of
attention because of their intriguing property of giving a strong
response to a small external stimulus. These stimuli can be
manifold, such as temperature,3 pH4 or light.5,6 The material
response might be a change in thickness, wettability and/or
color. For instance, a thermo-responsive hydrogel is a polymer
that exhibits a temperature-dependent thickness change in a
liquid environment. Such polymers are also researched for
biomedical applications because they can exhibit good biocom-
patibility and little to no toxicity within the body.7
Various approaches for polymeric encapsulation exist. For
instance, solution-processing by drop casting, spraying or ink-jet
printing, amongst others, can be employed. The drawback of these
techniques, however, is that solvent choice might be restricted
by the drug/regulatory or might lead to unwanted interactions
(e.g., (re)crystallization of the drug). However, there are also various
solvent-free techniques available, which do not succumb to these
limitations. Amongst them, initiated chemical vapor deposition
(iCVD) is one of the most potent techniques, allowing for the
synthesis of thin polymer films directly on various types of
substrates via a surface polymerization reaction.8 This solvent free
technique allows the application of a coating after drug loading,
without harming the drug layer. The iCVD technique allows the
deposition of conformal coatings with nanometer thickness
control, in a completely solvent-free environment. Moreover,
the chemical composition of the polymer layer can easily be
controlled9 with great fidelity on the functional groups of the
monomers.10 This is of great importance when a high percentage
of functional groups in the polymer is desired, e.g., in the case of
stimuli-responsive hydrogels.
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Using a thermo-responsive coating such as a copolymer of
N-isopropylacrylamide (NIPAAm), cross-linked with di(ethylene
glycol) divinyl ether (DEGDVE), p(NIPAAm-co-DEGDVE), McInnes
et al. demonstrated temperature-dependent drug delivery.11 This
is only possible because the polymer of NIPAAm, p(NIPAAm),
undergoes a reversible coil-to-globule transition at a lower critical
solution temperature (LCST) of about 32 1C, i.e. near the human
body temperature.12 In particular, the release of the drug campto-
thecin was demonstrated to be accelerated above the LCST. Other
studies demonstrated instead that pharmaceuticals such as
albumin13 and indomethacin14 give a faster release behavior
below the LCST. With some studies reporting faster deliveries
below the LCST and others above, it seems that there is not a
unique mechanism in which p(NIPAAm) liberates a pharma-
ceutical. Thus, the present work aims to further the under-
standing of which factors influence the delivery. For this
purpose, thin films of diﬀerent model drugs were encapsulated
in a p(NIPAAm-co-DEGDVE) hydrogel layer by iCVD. The drug
release experiments from the diﬀerent model drug delivery
systems were performed at diﬀerent temperatures and at diﬀerent
pH values. These data are complemented by a study of the pristine
drug layers and the polymer coatings, with a particular focus on
the temperature-dependent thickness change of the p(NIPAAm-co-
DEGDVE) hydrogel layer in a liquid environment.
Experimental
Conventional glass slides were used as substrates, cut into
2.5 2.5 cm2 pieces. Prior to usage, the substrates were cleaned
in an acetone ultrasonic bath for 15 min and rinsed with
deionized water. Three diﬀerent active pharmaceutical ingre-
dients (APIs) were used as model systems in the dissolution
tests: clotrimazole (Gatt-Koller GmbH, Austria), indomethacin
and phenytoin (both Sigma Aldrich, Germany). Their chemical
structures are depicted in Scheme 1 and all chemicals were of
pharmaceutical grade and used without any further purification.
API layers were deposited on the substrates by drop casting, from
tetrahydrofuran (THF, Merck, Germany) solutions at the follow-
ing concentrations: 2.5 mg mL1 for phenytoin, 28.6 mg mL1
for clotrimazole and 0.286 mg mL1 for indomethacin. 350 mL of
these solutions were drop cast on the glass. While phenytoin
crystallized within a fewminutes into the bulk phase,15 the other
drugs remained amorphous over the course of the experiments
or longer (up to days).
After ambient storage for 24 hours to evaporate any eventual
leftover solvent, a polymer coating was deposited on the samples
by iCVD to encapsulate the drug layer (see Scheme 1). A custom
build reactor setup was used as described in ref. 16. The mono-
mers NIPAAm and DEGDVE were heated to 85 1C and 70 1C,
respectively, and fed into the reactor through a heated mixing
line. The flow rates were controlled by needle valves. The initiator
tert-butylperoxide (TBPO) was kept at room temperature and fed
into the reactor through a mass flow controller. The flow rates
were 0.25 0.05 sccm for NIPAAm, 0.80 0.15 sccm for DEGDVE
and 0.50  0.05 sccm for TBPO. The depositions were performed
at a constant working pressure of 200 mTorr, with the substrate
and filament temperatures at 30 1C and 250 1C, respectively. The
polymer layers were grown up to a thickness of 200 nm, moni-
tored in situ by laser interferometry.
To test the amount of drug release from the surface either
without or with the hydrogel encapsulations, the samples were
immersed into 50 mL of a buﬀer solution of NaH2PO4 at
diﬀerent pH values, to simulate either stomach (pH 1.5–3.5)
or neutral environments. Furthermore, the temperatures
were kept at either 37 1C or 25 1C to be above and below the
LCST. During the entire experiment the samples were shaken
using a standard shaking device minimizing diffusion problems
due to convection absence. The dissolution medium was
sampled every 10 min by withdrawing 500 mL of the solu-
tion, thus resulting in a small reduction of dissolution volume
over time, which was accounted for in the concentration
determination using high performance liquid chromatography
(HPLC).
For HPCL measurements, internal standards (ISTD) were
added to the analyte, to evaluate potential experimental errors.
5 mg mL1 of phenytoin in acetonitrile was used for indomethacin
evaluation and 100 mg mL1 indomethacin in acetonitrile was
used for phenytoin and clotrimazole evaluation. Prior to injection
of the sample into the HPLC, the solvents were evaporated at
95 1C under a nitrogen atmosphere (TECHNE Sample Concen-
trator). 100 mL of acetonitrile (ACN) re-dissolved the drug and the
internal standard, which was then measured using UV-vis absorp-
tion. Each experiment was repeated three times and the error is
given as standard deviation.
The thickness of the polymer thin films and the temperature-
dependent swelling were evaluated on bare silicon substrates
without the drug layer, by spectroscopic ellipsometry (J.A. Woollam
M-2000). Data acquisition was performed in air at three angles
(65, 70 and 751) in the wavelength range from 370 to 1000 nm.
Data were evaluated using simulations with an optical model
comprised of three layers; the silicon substrate, the native
silicon dioxide (1.7 nm) and a Cauchy layer representing the
polymer. The hydrogel swelling behavior in both buﬀer solution
(pH = 3) and buﬀer plus API (at 15 mg mL1) was also explored
by in situ ellipsometry at a fixed angle of 751, utilizing a heated
liquid cell (Woollam, USA). The temperature was ramped from
room temperature to 50 1C at a rate of 1 1C min1. The eﬀective
Scheme 1 Chemical formulae of the diﬀerent model pharmaceuticals
tested within this study and the sample arrangement.
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medium approximation (EMA) was used to model the composite
consisting of polymer and water. The model mixes the optical
constants of water with those of the dry Cauchy layer (i.e.
polymer) according to their relative fraction (which is the fitting
parameter).
Results and discussion
The deposition of the p(NIPAAM-co-DEGDVE) using iCVD resulted
in a homogeneous coating on top of the silicon substrate.
The thickness of this layer was chosen to be about 200 nm
since this represents a good trade-oﬀ between deposition time
and sample performance, as demonstrated earlier.9 The surface
roughness was about 1 nm. The chemical characterization was
shown previously, demonstrating the retention of the func-
tional groups.17
The temperature-dependent swelling of the p(NIPAAM-co-
DEGDVE) film for two diﬀerent environments is shown in
Fig. 1. Upon immersion of the layer into a NaH2PO4 buﬀer
solution at pH = 3, the polymer is already in its equilibrium
swollen state at 20 1C, exhibiting a 30% thickness increase from
the dry state (from 200 nm to 261 nm) (Fig. 1a). As the tem-
perature increases, the layer thickness decreases steadily with
the greatest rate of change (slope) at 29 1C. This temperature was
identified as the LCST of the p(NIPAAM-co-DEGDVE) layer we
synthesized. Below this temperature, the hydrogel is predomi-
nantly in its highly swollen state, while it gradually collapses at
elevated temperatures. When the temperature reaches 50 1C,
the layer shrinks to almost its initial dry thickness of 200 nm,
suggesting that most of the free water is pushed out of the
polymer.
The experiment was repeated with phenytoin as a model
drug being added to the buﬀer solution to identify any potential
interaction of the drug with the polymeric layer and its swelling
behavior. Such temperature-dependent swelling profile is shown
in Fig. 1b for the case of dissolved phenytoin. The transition
from the swollen to the shrunken state still occurred but was less
pronounced overall. The equilibrium thickness at 20 1C was just
225 nm. Again, heating led to a thickness reduction and at 50 1C
the layer was collapsed into its initial, dry thickness. As pheny-
toin is poorly soluble in the buﬀer solution, the solvation ability
of the buﬀer towards the polymer coils is reduced when pheny-
toin is present (similar to the salting-out of macromolecules).
Thus, the poorer solvent quality results in less expansion as
solvent contact is unfavorable. In addition, when phenytoin is
present in the medium, the transition from swollen to shrunken
occurs at a lower LCST: 22 1C instead of 29 1C. This means that
the hydrogel needs less energy to remove the solution from
within its meshes, hinting that the solvation forces are strongly
altered.
Commonly, hydrogels release solutes following the free
volume theory: the solutes can permeate the expanded polymer
network much faster as the increased free volume in the matrix
provides more diﬀusion paths through the system. To test this
assumption, we performed dissolution experiments at two
diﬀerent temperatures in NaH2PO4 buﬀer, adjusted to pH = 3.
In Fig. 2, the results for phenytoin, clotrimazole and indo-
methacin are summarized. The acidic dissolution media and
the temperature of 37 1C were chosen to mimic the human
digestive tract. The second dissolution temperature, 25 1C, was
chosen to be below the lower critical solution temperature
(LCST) of our hydrogel coating (i.e. the polymer is in the highly
swollen state). Even though this temperature is not physiological,
it gives a good insight into the thermo-responsive behavior of the
coating and how it aﬀects the drug release.
For the bare phenytoin samples, i.e. without coating, a steady
release behavior is noted for the thin films (see Fig. 2a, black and
red curves), with the release rate gradually declining after about
60% of phenytoin has been released from the surface. For both
temperatures tested (25 1C and 37 1C), about 20% of the drug
load was dissolved within the first 60 minutes. After this initial
stage, the release at 37 1C proceeded with a steeper slope.
After 400 min, about 50% was released at 25 1C and more than
60% at the elevated temperatures. Measurements taken after
1400 minutes show that full release was achieved at both tem-
peratures. It should be noted, that the release profile can be
changed when themorphology18 or the polymorph is changed,15,19
but to identify the impact of the coating, it is important to generate
reproducible drug films of identical properties, which was the
focus of this study.
The phenytoin encapsulated by a p(NIPAAm-co-DEGDVE)
layer instead was released with a strong delay. In particular,
at 25 1C only negligible drug release occurred within the first
Fig. 1 Temperature-induced swelling profiles of the p(NIPAAM-co-DEGDVE)
hydrogel when exposed to a NaH2PO4 buﬀer at pH = 3 (top) or exposed to a
solution containing phenytoin dissolved in the same buﬀer. The two curves
share a common abscissa.
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180 minutes and after 360 minutes, less than five percent had
been released. After 1400 minutes, about a quarter of the total
mass had been liberated. This is surprising as ellipsometric
measurements tell that the layer is in its swollen state at this
temperature while the layer collapses at 37 1C. At increased
temperatures a much faster release behavior is noted, similar to
that of bare phenytoin at 25 1C. Within 1400 minutes, 70% had
been released. At this stage little release occurs, meaning that
some phenytoin will likely remain entrapped under or within
the polymer network.
A similar behavior was displayed by the drugs clotrimazole
and indomethacin but with diﬀerences in the time scales. This
is in part attributed to the solid state of these drugs. During
sample preparation, both clotrimazole and indomethacin
remained amorphous while phenytoin rapidly crystallized.
The dissolution of an amorphous layer is in general faster since
there is less energy required for molecules to transit in the
solvated state from the solid–liquid interface.9 The impact of
the crystalline state on the indomethacine release is shown in
ref. 20. This along with differences in the intrinsic solubilities
causes a significantly faster release for both pharmaceuticals
when compared to phenytoin under the same experimental
conditions. Further, drug–substrate interactions as well as the
wettability of the different systems might vary.
The encapsulation resulted also in a retarded release behavior
of clotrimazole and indomethacin below the LCST of the
hydrogels. For clotrimazole, 55% of the drug was released at
37 1C and only 10% at 25 1C. The indomethacin, instead was
released with a higher slope at 37 1C but the total amount
released after 1400 minutes was the same as at 25 1C, diﬀerently
from the case of the other two drugs investigated.
To evaluate the release curves in more detail, mathematical
models are fitted to the experimental data. Two diﬀerent
models are utilized which provide some insight into the diﬀer-
ences of the samples investigated. For many of the more
sophisticated models described in the literature, a detailed
parametrization of the polymer system is required (e.g. deter-
mination of the molecular weight). Such detailed analysis of
iCVD polymers is often diﬃcult or outright impossible because
of the small quantity of polymer thin films produced. In addi-
tion, these models are mostly aimed at standard dissolution
experiments, i.e. using standard dosage forms such as tablets
or capsules, and not drug thin films as in this case. Therefore
instead of a too elaborated data analysis, simple models such
as the one by Korsmeyer and Peppas were used to obtain
an idea about diﬀerences in the transport mechanism. The
Korsmeyer and Peppas model well describes the release
behavior up to a fractional release of about 60%. Along with
the Korsmeyer–Peppas model, we use a simplified exponential
model, which is based on analytic description of the release
behavior of the slab geometry present in the current study. This
model describes the time-dependence of the fractional release
Mt/MN by
Mt
M1
¼Mmax 1 ekert
 
(1)
Here, ker is an effective release constant andMmax estimates the
maximum amount of drug release from the system under
investigation. Fits to the experimental data from Fig. 2 are
summarized in Table 1. The fits and our experimental data are
in reasonable agreement with the coefficient of determination
R2, being above 0.97. The Mmax values vary according to the
maximum amount being released, as evident from the curves in
Fig. 2. This suggests that in the presence of the polymer
encapsulation, part of the drug remains entrapped and cannot
be released from the system, or at least it would take much
longer.
The release constants show that the amorphous drug films
(i.e. clotrimazole and indomethacin) released almost twice as
fast at 37 1C than at 25 1C. For the crystalline sample, i.e.
phenytoin, the temperature dependence is evenmore pronounced,
with the ratio k371C/k251C being 2.65.
Fig. 2 Drug release profiles of phenytoin (a), clotrimazole (b) and indo-
methacin (c) all measured either at 25 1C and 37 1C in NaH2PO4 buﬀer (pH = 3).
For each drug, data of bare and of coated samples (200 nm) of p(NIPAAm-co-
DEGDVE) are shown. Data points represent experimental data with standard
deviation. Full lines represent fits with themodel in eqn (1). The diﬀerent graphs
share a common x-axis.
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According to Korsmeyer and Peppas, the drug release from a
polymeric system can be described by the simple formula:
Mt
M1
¼ k  tn (2)
where k is another release constant and n is the release
exponent. The exponent n allows for an estimate of the trans-
port mechanism with which liberation from the sample into
the surrounding dissolution medium occurs. The meaning of
the exponent depends on the shape of the system.21 For a thin
film, n equal to 0.5 is attributed to Fickian diﬀusion, while
0.5 o n o 1 occurs for non-Fickian diﬀusion. An exponent of
1 corresponds to case II transport or zero order release and for
values greater than 1, super case II transport is present. As the
exact release mechanism is unknown, here we also fit the
release exponent to obtain some idea about the release mecha-
nism. The exponent values n are reported in Table 1. For the
bare drug layers, this exponent varies between 0.85 and 1. This
value is well within the anomalous transport i.e. within the
release process the diﬀusion is non-linear with time, diﬀerently
from typical conventional diﬀusion. Similarly, the evaluation of
the coated samples shows that the exponent increased to 1 and
above. Such exponential values are a strong indication that a
zero order release is involved, whereby a zero-order release
describes the capability to deliver drug at a constant rate, thus
providing a predictable bioavailability status over a long time.22
In comparison, the clotrimazole sample at 25 1C shows a much-
reduced exponent compared to all others, therefore this is the
only sample behaving according to Fickian diﬀusion.
Considering that in a swollen layer there is more free volume
for drug diﬀusion, one would have expected to obtain faster
release at lower temperatures for our encapsulated layers. The
results unexpectedly show, however, that the release of all drugs
is faster at higher temperatures when measured at pH = 3. One
possible explanation could be related to the coil-to-globule
transition: below the LCST, the polar amide groups are exposed
towards the interphase with the environment, leading to the
formation of H-bonding with water molecules and swelling.
Above the LCST, the configuration changes and the apolar iso-
propyl groups are exposed at the interphase with the environ-
ment instead. Since all molecules have polar hydrophilic sites,
it is likely that also the drug molecules form H-bonds with
the hydrogel and remain entrapped in the network without
dissolving into the free dissolution medium. Furthermore, the
increase in temperature means that the drug release from the
bare film is at least two times faster, since diﬀusion increases
with temperature. Both eﬀects might very well overcompensate
for a poorer permeability through a collapsed hydrogel.
It is worth noticing that among the three model drugs, indo-
methacin is the one with the lowest logarithmic acid dissocia-
tion constant, pKa = 4.5. Therefore, in our acidic environment
the indomethacin has the carboxylic group in its undissociated
state. At pH = 7, instead, the indomethacin is in its dissociated
form which is more soluble in water. Therefore we studied also
the release at neutral pH, and the results are shown in Fig. 3.
The dissolution studies of the bare indomethacin at pH = 7
show a very rapid release so that 100% of the drug is burst into
the surrounding media within the first 5 minutes. A change
in the temperature did not change the release behavior of the
bare drug significantly, at least within the limit of the used time
resolution for these experiments (2 minutes).
When the indomethacin film is encapsulated into the
p(NIPAAM-co-DEGDVE), the temperature-dependence of the
release changes drastically at pH = 7, especially when compared
to the behavior at pH = 3 (cf. 2 and 3, but please mind the
diﬀerent time scaling). Hereby, at 37 1C, the dissolution of the
drug seems to be very quick with a corresponding release
exponent k = 99.05  103 min1. Surprisingly, the maximum
amount of indomethacin released at pH = 7 from under the
coating is just 28% and is reached already after 30 minutes. At
37 1C the layer is collapsed, which means the free volume for
molecular diﬀusion is small.
At 25 1C the polymer coating layer is swollen and the release
is a bit quicker in terms of mass transfer over time compared to
Table 1 Summary of the dissolution data from the various samples and
the modeling according to eqn (1) and (2) with Mmax being the estimated
maximum release, ker being the eﬀective release constant, R
2 being the
coeﬃcient of determination for the fit with model 1 and n being the
exponent of the fits using eqn (2)
Material Coating T [1C]
Mmax
[%/100]
ker
[103 min1] R2
n
(Kors. Peppa)
Phen  25 1.00 1.37 0.97 0.877
 37 1.00 3.64 0.99 0.948
+ 25 0.43 0.18 0.99 1.348
+ 37 0.71 3.09 0.97 1.063
Clot  25 1.00 10.42 0.98 0.828
 37 1.00 20.41 0.99 0.950
+ 25 0.12 0.79 1.00 0.471
+ 37 0.38 4.88 1.00 1.386
Indo  25 1.00 9.35 0.97 0.870
 37 1.00 20.43 0.98 0.853
+ 25 0.25 2.07 1.00 1.067
+ 37 0.59 3.79 1.00 1.108
Indo pH 7  25 Burst release
 37 Burst release
+ 25 0.73 24.40 0.99 0.685
+ 37 0.28 99.05 0.97 0.717
Fig. 3 Drug release at diﬀerent temperatures for indomethacin bare and
encapsulated within 200 nm of p(NIPAAm-co-DEGDVE). The dissolution
medium was NaH2PO4 at pH = 7.
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that at 37 1C. The maximum amount able to escape the dosage
form is 73% which is about 2.6 more compared to indomethacin
samples at 37 1C. It should be kept in mind that the diﬀerence in
pH is not expected to influence the secondary amino group of
NIPAAm, since both pH values in the experiments (pH = 3 and 7)
are below the pKb typical of this functional group and also
swelling experiments did not show any significant diﬀerences
(data not shown). So the much faster release can be explained by
the larger free volume formed in the swollen state.
The question arises, why at pH = 7 the larger free volume
actually provides better molecular transport into the dissolu-
tion medium while at pH = 3 the situation seems to be reversed
(see Fig. 4). First of all, the solubility of indomethacin changes
drastically meaning that dissolution at the boundary layer is
strongly enhanced. Higher solubility also means that the diﬀu-
sion behavior changes as molecule–molecule interactions are
less problematic. This can be followed by the change of the
exponent using the Korsmeyer–Peppa model, which decreases
well below 1 for pH = 7 while it is above 1 at pH = 3. The
deprotonation of indomethacin at pH = 7 might also alter the
interaction with the NIPAAm so that the effect of vacant volume
sites created upon swelling, i.e. at low temperature, is nowmore
dominant than the temperature and H-bonding effects on
diffusion. At high temperatures and neutral pH, upon chains
collapsing, the number of free paths towards the dissolution
medium reduces and more drug material remains entrapped.
Conclusions
The objective of this work was to demonstrate which conditions
(pH, drug solubility) aﬀect the temperature-dependent release of
diﬀerent drugs encapsulated by a hydrogel layer of p(NIPAAM-co-
DEGDVE) deposited by iCVD. This polymer undergoes a fast coil-
to-globule transition at the low critical solution temperature,
which was estimated around 29 1C or 22 1C in the presence of a
drug. Above these temperatures, the hydrogel is in its shrunken,
collapsed state in which the apolar isopropyl groups are exposed
towards the interface with the environment. Below the LCST,
the conformation of the polymer changes, the polar groups are
exposed towards the interface and the polymer can adsorb
water in its meshes.
At low pH, all model drugs were released faster above the
LCST, when the polymer is in its collapsed state. This was
ascribed to the formation of H-bonds between the polymer and
the drugs. Such strong interaction is enhanced when the polar
groups are exposed towards the interphase, e.g. below the LCST.
The bonding between the rather hydrophobic drug molecules
chosen and the polymer trapped the drugs, hindering their
release. This is also reflected by the reduction of swelling
capabilities, when there is some phenytoin present in the buﬀer
solution. At neutral pH, the release behavior for indomethacin
was reversed: a faster release was recorded below the LCST,
i.e. when the polymer is in its swollen state. At this pH the
indomethacin is in its deprotonated form and therefore less
prone to form H-bonding with the polymer. In this case, thus,
the release was faster when more free volume was available, i.e.
in the shrunken state, below the LCST.
The findings in here show, that the molecular species as well
as the polymer itself have a great impact on the dissolution
behavior. This provides clarity to the somehow contradicting
literature results previously observed from various research
groups dealing with p(NIPAAM). In fact, it is not only the LCST
but also the polymer–drug interaction that governs the drug
release, which might also be used to gain further control over
responsive behavior.
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